RESUMEN
Smad4 is a candidate tumour-suppressor gene identified recently on chromosome 18q21.1. Both alleles are inactivated in nearly one-half of pancreatic carcinomas, but its role in the tumorigenesis of other tumours is still unknown. The aim of this study was to investigate the potential involvement of the Smad4 locus in early-stage colorectal cancers (stages I-III) in tumour samples from a randomised multicentre trial. Of a large collection of DNA samples, 73 with a loss of one allele of the Smad4 gene were analysed for the presence of point mutations in the remaining gene. Patients, from whom biopsies were isolated, were part of a previous randomised multicentre study of the Swiss Group for Clinical Cancer Research on the benefit of adjuvant chemotherapy (SAKK study 40/81). Mutation analysis was restricted to the highly conserved C-terminal domain (exons 8, 9, 10 and 11) of Smad4, using PCR and single-strand conformational variant analysis. Two of the 73 patients (3%) with loss of one allele of Smad4 had a point mutation in the remaining allele. These results indicate that whereas Smad4 point mutations are prevalent in pancreatic carcinoma, they are infrequent in early stages (I-III) of colorectal cancer.
Asunto(s)
Neoplasias Colorrectales/genética , Proteínas de Unión al ADN/genética , Pérdida de Heterocigocidad , Transactivadores/genética , Ensayos Clínicos como Asunto , Dosificación de Gen , Humanos , Mutación , Estadificación de Neoplasias , Proteína Smad4RESUMEN
The gene for the transducer of transforming growth factor-beta/bone morphogenetic protein signalling SMAD4, a potential suppressor of colorectal carcinogenesis, is located at the chromosomal region 18q21. In order to evaluate the clinical relevance of SMAD4 deletion, gene copy alterations were determined by copy dosage using real-time quantitative PCR in 202 colorectal tumour biopsies from a previous randomised study of adjuvant chemotherapy. Patients with normal SMAD4 diploidy turned out to have a three-fold higher benefit of 5-fluorouracil-based adjuvant chemotherapy with a border line significance (overall survival: 3.23, P=0.056; disease-free survival: 2.89, P=0.045). These data are consistent with the previous observation that patients whose cancer had retention of the 18q21 region had a significantly higher benefit from 5-fluorouracil-based therapy. Moreover, these results may provide a refinement at the gene level of the clinical relevance of 18q21 deletion, thereby suggesting SMAD4 as a predictive marker in colorectal cancer. This data also indicate that integrity of this component of the transforming growth factor-beta/bone morphogenetic protein signalling pathway may be a critical factor for benefit of chemotherapy in patients with colorectal cancer.
Asunto(s)
Antimetabolitos Antineoplásicos/uso terapéutico , Cromosomas Humanos Par 18/genética , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/genética , Proteínas de Unión al ADN/genética , Fluorouracilo/uso terapéutico , Dosificación de Gen , Transactivadores/genética , Biomarcadores , Quimioterapia Adyuvante , Deleción Cromosómica , Cartilla de ADN/química , ADN de Neoplasias/metabolismo , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Valor Predictivo de las Pruebas , Pronóstico , Ensayos Clínicos Controlados Aleatorios como Asunto , Transducción de Señal/genética , Proteína Smad4 , Tasa de Supervivencia , Factor de Crecimiento Transformador beta/genéticaRESUMEN
Deletions of chromosome band 18q21 appear with very high frequency in a variety of carcinomas, especially in colorectal cancer. Potent tumor suppressor genes located in this region encode transforming growth factor beta (TGF-beta) signal transducers SMAD2 and SMAD4, and inactivation of either one leads to impaired TGF-beta-mediated cell growth/apoptosis. Following the assignment of SMAD7 to 18q21, we first refined the SMAD7 gene position within this region by genetically mapping SMAD7 between SMAD2 and SMAD4. Further, to compare the respective frequencies of genetic alterations of these three SMAD genes in colorectal cancer, we undertook a large-scale evaluation of the copy status of each of these genes on DNA samples from colorectal tumor biopsy material. Among a subset of 233 DNA samples for which data were available for all four genes, SMAD4, SMAD2, and the nearby gene DCC showed high deletion rates (66%, 64%, and 59%, respectively), whereas SMAD7 was deleted in only 48% of the tumors. Unexpectedly, we found some gene duplications; SMAD7 appears to be more frequently amplified (10%) than the three other genes (4-7%). Compiled data for SMAD genes in each tumor show that the most common combination (26% of all the tumors) consists of the simultaneous deletions of SMAD2 and SMAD4 associated with normal diploidy or even duplication of SMAD7. Since SMAD7 normally counteracts SMAD2 and SMAD4 in TGF-beta signaling, we hypothesize that the tumor might not benefit from simultaneous SMAD7 inactivation, thereby exerting selective pressure to retain or even to duplicate the SMAD7 gene.
Asunto(s)
Cromosomas Humanos Par 18/genética , Neoplasias Colorrectales/genética , Proteínas de Unión al ADN/genética , Dosificación de Gen , Transactivadores/genética , Deleción Cromosómica , Mapeo Cromosómico , Orden Génico , Genes Sobrepuestos/genética , Genes Supresores de Tumor/genética , Humanos , Transducción de Señal/genética , Proteína Smad2 , Proteína Smad4 , Proteína smad7 , Factor de Crecimiento Transformador beta/genéticaRESUMEN
A selection of World Wide Web sites relevant to papers published in this issue of Current Opinion in Biotechnology.
Asunto(s)
Biotecnología/métodos , Microbiología Ambiental/normas , Internet , Animales , Fungicidas Industriales/normas , HumanosRESUMEN
A selection of World Wide Web sites relevant to papers published in this issue of Current Opinion in Biotechnology.
Asunto(s)
Biotecnología/métodos , InternetRESUMEN
A selection of World Wide Web sites relevant to papers published in this issue of Current Opinion in Biotechnology.
Asunto(s)
Biotecnología , Industria Química , Tecnología Farmacéutica , Técnicas Químicas Combinatorias , InternetRESUMEN
Alterations in the tumor suppressor gene p53 lead to impaired cell cycle control, allowing for the development and growth of tumors. To restore a loss of p53 function, we performed a phase I study of intratumoral gene therapy with adenovirus expressing wild-type p53 in patients with non-small cell lung cancer carrying mutations in the p53 gene. Furthermore, in a phase II study, gene therapy was complemented with simultaneous cisplatin/vinorelbine treatment. Biopsies were obtained from all treated patients before and 24-48 hours after gene therapy to study changes in the expression of p53 target genes. We report here that in most of the cases, the target gene p21 was up-regulated, especially when injection of higher doses of p53-expressing adenovirus was combined with simultaneous chemotherapy, whereas Pig3, previously reported to be highly up-regulated by p53, generally did not show a clear increase. Interestingly, a clear p21 gene response was observed only in tumors showing stabilization or regression. We conclude that p21 appears to be up-regulated after adenovirus-mediated p53 gene transfer and is the most sensitive marker tested for biological response to gene therapy in the small cohort of non-small cell lung cancers that were studied.
Asunto(s)
Adenoviridae/genética , Carcinoma de Pulmón de Células no Pequeñas/terapia , Genes p53/genética , Terapia Genética , Neoplasias Pulmonares/terapia , Biosíntesis de Proteínas , Proteínas Proto-Oncogénicas , Vinblastina/análogos & derivados , Proteínas de Unión al GTP rho/biosíntesis , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Cisplatino/administración & dosificación , Terapia Combinada , Cartilla de ADN/química , Femenino , Vectores Genéticos , Humanos , Inyecciones/métodos , Péptidos y Proteínas de Señalización Intracelular , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Masculino , Mortalidad , Proteínas/genética , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transfección/métodos , Resultado del Tratamiento , Vinblastina/administración & dosificación , Vinorelbina , Proteínas de Unión al GTP rho/genéticaRESUMEN
OBJECTIVE: the aim of this work was to quantify the intensity of the vasodilation induced by dipyridamole used to simulate a stress test during a myocardial tomoscintigraphy. METHODS: Doppler measurements of the femoral artery and the thoracic aorta were made on 26 patients (11 men, 15 women), using transducers attached to the skin, measurements being performed every 2 min during the 10 min of the stress test. The following parameters were measured: (a) the vascular resistance index of the lower limbs defined as R(fa)=D/S with S and D, respectively, the maximum amplitude of the systolic wave and the maximum amplitude of the diastolic reflux measured on the Doppler femoral spectrogram; (b) the aortic and femoral blood flows obtained from the mean velocity on the Doppler spectrogram. RESULTS: 14 of the 26 patients (54%) showed a significant vasodilation (i.e. a decrease of R(fa) of more than 10%). Eighty-seven percent of the patients with a positive myocardial scintigraphy showed a vasodilation. Sixty-six percent of patients who had prior vasodilator treatment showed no vasodilation. A slight decrease in blood pressure was observed for vasodilated patients but also for non-vasodilated patients. The aortic flow increased slightly for all patients. CONCLUSIONS: Doppler monitoring of femoral vascular resistance is a useful method for quantifying the dipyridamole-induced vasodilation, and hence the stress level upon which the diagnostic efficiency of myocardial scintigraphy is depending. Our study demonstrates that testing with dipyridamole was inconclusive in 66% of patients who had already vasodilator treatment.
Asunto(s)
Dipiridamol , Corazón/diagnóstico por imagen , Pierna/irrigación sanguínea , Ultrasonografía Doppler , Resistencia Vascular/efectos de los fármacos , Vasodilatadores , Aorta Torácica/diagnóstico por imagen , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Femenino , Arteria Femoral/diagnóstico por imagen , Hemodinámica/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Cintigrafía , Vasodilatación/efectos de los fármacosAsunto(s)
Biotecnología , Quimioterapia , Genética Médica , Humanos , Internet , Publicaciones Periódicas como AsuntoRESUMEN
Understanding the molecular mechanisms regulating the expression of interleukin 4 (IL-4) may shed light on the differentiation of lymphokine-producing phenotypes of CD4+ T cells. We have identified two DNA segments that are necessary for full phorbol 12-myristate 13-acetate (PMA)-induced activity of the IL-4 promoter region in the thymoma cell line EL4. Through deletion and mutation analyses, one of these segments (-57 through -47) was shown to be indispensable for promoter function. We designated this sequence consensus sequence 1 (CS1), as it shares homology with a sequence (ATTTTCCNNTG) that appears five times in the proximal 302-base-pair (bp) region 5' of the gene. We examined CS1 in further detail, as well as a second consensus sequence, CS2, located at nucleotides -75 through -65; both are within a minimal 83-bp construct that expresses full promoter activity. CS1- and CS2-spanning oligonucleotides bound apparently distinct PMA-inducible, sequence-specific factors in mobility-shift assays. Multimer constructs linking CS1- or CS2-spanning oligonucleotides to a heterologous promotor revealed that the CS1 construct had the greater enhancer activity in EL4 cells. Mutating the CS1 sequence within the context of the 302-bp promoter abolished all activity of the promoter, while mutating the CS2 sequence alone had little effect. Furthermore, a CS1 multimer could drive a heterologous promoter in an IL-4-producing [helper T-cell type 2 (TH2-type)] T-cell clone but not in a non-IL-4-producing (TH1-type) clone, suggesting a mechanism by which IL-4 production could be differentially regulated in TH subsets.